The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy.
Gazyva was previously approved for treating certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.
